Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.

Arroyo R, Bury DP, Guo JD, Margolin DH, Melanson M, Daizadeh N, Cella D.

Mult Scler. 2019 May 30:1352458519849796. doi: 10.1177/1352458519849796. [Epub ahead of print]

PMID:
31144568
2.

Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.

Phelps R, Winston JA, Wynn D, Habek M, Hartung HP, Havrdová EK, Markowitz GS, Margolin DH, Rodriguez CE, Baker DP, Coles AJ.

Mult Scler. 2019 Aug;25(9):1273-1288. doi: 10.1177/1352458519841829. Epub 2019 Apr 15.

PMID:
30986126
3.

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.

Cuker A, Bass AD, Nadj C, Agius MA, Steingo B, Selmaj KW, Thoits T, Guerreiro A, Van Wijmeersch B, Ziemssen T, Meuth SG, LaGanke CC, Thangavelu K, Rodriguez CE, Baker DP, Margolin DH, Jannsens A.

Mult Scler. 2019 Feb 20:1352458518816612. doi: 10.1177/1352458518816612. [Epub ahead of print]

PMID:
30785358
4.

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.

Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, Hartung HP, Selmaj KW, Weiner HL, Daizadeh N, Margolin DH, Chirieac MC, Compston DAS.

Mult Scler. 2018 Oct 5:1352458518796675. doi: 10.1177/1352458518796675. [Epub ahead of print]

PMID:
30289355
5.

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.

6.

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ; CARE-MS I and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1107-1116. doi: 10.1212/WNL.0000000000004313. Epub 2017 Aug 23. Erratum in: Neurology. 2018 Apr 17;90(16):755.

7.

Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.

Arroyo González R, Kita M, Crayton H, Havrdova E, Margolin DH, Lake SL, Giovannoni G; CARE-MS I and II Investigators.

Mult Scler. 2017 Sep;23(10):1367-1376. doi: 10.1177/1352458516677589. Epub 2016 Nov 25.

PMID:
27885061
8.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

9.

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.

Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni G, Hartung HP, Havrdova E, Selmaj KW, Stojanovic M, Weiner HL, Lake SL, Margolin DH, Thomas DR, Panzara MA, Compston DA; CARE-MS I and CARE-MS II Investigators.

Neurology. 2016 Oct 4;87(14):1464-1472. Epub 2016 Sep 2.

10.

Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.

Fox EJ, Wynn D, Coles AJ, Palmer J, Margolin DH; CAMMS223 Investigators.

J Neurol Sci. 2016 Apr 15;363:188-94. doi: 10.1016/j.jns.2016.02.025. Epub 2016 Feb 12.

11.

Prevention and Management of Infusion-Associated Reactions in the Comparison of Alemtuzumab and Rebif(®) Efficacy in Multiple Sclerosis (CARE-MS) Program.

Caon C, Namey M, Meyer C, Mayer L, Oyuela P, Margolin DH, Rizzo M.

Int J MS Care. 2015 Jul-Aug;17(4):191-8. doi: 10.7224/1537-2073.2014-030.

12.

Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.

Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, Palmer J, Margolin DH, Hollenstein J.

J Clin Endocrinol Metab. 2014 Jan;99(1):80-9. doi: 10.1210/jc.2013-2201. Epub 2013 Dec 20.

PMID:
24170099
13.

Ataxia, dementia, and hypogonadotropism caused by disordered ubiquitination.

Margolin DH, Kousi M, Chan YM, Lim ET, Schmahmann JD, Hadjivassiliou M, Hall JE, Adam I, Dwyer A, Plummer L, Aldrin SV, O'Rourke J, Kirby A, Lage K, Milunsky A, Milunsky JM, Chan J, Hedley-Whyte ET, Daly MJ, Katsanis N, Seminara SB.

N Engl J Med. 2013 May 23;368(21):1992-2003. doi: 10.1056/NEJMoa1215993. Epub 2013 May 8.

14.

Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.

Graves J, Galetta SL, Palmer J, Margolin DH, Rizzo M, Bilbruck J, Balcer LJ.

Mult Scler. 2013 Sep;19(10):1302-9. doi: 10.1177/1352458513475722. Epub 2013 Mar 4.

15.

Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis.

Meyer D, Coles A, Oyuela P, Purvis A, Margolin DH.

Mult Scler Relat Disord. 2013 Jan;2(1):60-3. doi: 10.1016/j.msard.2012.07.002. Epub 2012 Sep 25.

PMID:
25877456
16.

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators.

Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.

PMID:
23122652
17.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
18.

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.

Neurology. 2012 Apr 3;78(14):1069-78. doi: 10.1212/WNL.0b013e31824e8ee7. Epub 2012 Mar 21.

PMID:
22442431
19.

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

Cuker A, Coles AJ, Sullivan H, Fox E, Goldberg M, Oyuela P, Purvis A, Beardsley DS, Margolin DH.

Blood. 2011 Dec 8;118(24):6299-305. doi: 10.1182/blood-2011-08-371138. Epub 2011 Sep 29.

20.

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.

Lancet Neurol. 2011 Apr;10(4):338-48. doi: 10.1016/S1474-4422(11)70020-5.

PMID:
21397567
21.

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK.

N Engl J Med. 2008 Oct 23;359(17):1786-801. doi: 10.1056/NEJMoa0802670.

22.

Germinal center function in the spleen during simian HIV infection in rhesus monkeys.

Margolin DH, Saunders EH, Bronfin B, de Rosa N, Axthelm MK, Goloubeva OG, Eapen S, Gelman RS, Letvin NL.

J Immunol. 2006 Jul 15;177(2):1108-19.

23.

Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual.

Du Pasquier RA, Corey S, Margolin DH, Williams K, Pfister LA, De Girolami U, Mac Key JJ, Wüthrich C, Joseph JT, Koralnik IJ.

Neurology. 2003 Sep 23;61(6):775-82.

PMID:
14504320
24.

Challenges of single-cell diagnostics: analysis of gene expression.

Todd R, Margolin DH.

Trends Mol Med. 2002 Jun;8(6):254-7. Review.

PMID:
12067605
25.

Hypogonadotropic hypogonadism and cerebellar ataxia: detailed phenotypic characterization of a large, extended kindred.

Seminara SB, Acierno JS Jr, Abdulwahid NA, Crowley WF Jr, Margolin DH.

J Clin Endocrinol Metab. 2002 Apr;87(4):1607-12.

PMID:
11932290
26.

High frequency of virus-specific B lymphocytes in germinal centers of simian-human immunodeficiency virus-infected rhesus monkeys.

Margolin DH, Saunders EF, Bronfin B, de Rosa N, Axthelm MK, Alvarez X, Letvin NL.

J Virol. 2002 Apr;76(8):3965-73.

27.

Stimulation of antiviral antibody response in SHIV-IIIB-infected macaques.

Muller S, Margolin DH, Min G, Lou D, Nara P, Axthelm MK, Kohler H.

Scand J Immunol. 2001 Oct;54(4):383-95.

28.

Clinicopathological characterization of an HIV-2-infected individual with two clonally unrelated primary lymphomas.

Kempf W, Margolin DH, Dezube BJ, Kadin ME, Letvin NL, Koralnik IJ.

Am J Hematol. 2000 Dec;65(4):302-6.

PMID:
11074559
29.

Germline repertoire of the immunoglobulin V(H)3 family in rhesus monkeys.

Helmuth EF, Letvin NL, Margolin DH.

Immunogenetics. 2000 Jun;51(7):519-27.

PMID:
10912503
30.

Stimulation of HIV-1-neutralizing antibodies in simian HIV-IIIB-infected macaques.

Müller S, Margolin DH, Nara PL, Alvord WG, Köhler H.

Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):276-81.

31.

Immunoglobulin V(H) usage during primary infection of rhesus monkeys with chimeric simian-human immunodeficiency viruses.

Margolin DH, Reimann KA, Sodroski J, Karlsson GB, Tenner-Racz K, Racz P, Letvin NL.

J Virol. 1997 Nov;71(11):8582-91.

33.

HIV-1 gp120: a novel viral B cell superantigen.

Townsley-Fuchs J, Neshat MS, Margolin DH, Braun J, Goodglick L.

Int Rev Immunol. 1997;14(4):325-38. Review.

PMID:
9186784
34.

Endogenous opiate reward induced by an enkephalinase inhibitor, thiorphan, injected into the ventral midbrain.

Glimcher PW, Giovino AA, Margolin DH, Hoebel BG.

Behav Neurosci. 1984 Apr;98(2):262-8.

PMID:
6586195
35.

Neurotensin: a new 'reward peptide'.

Glimcher PW, Margolin DH, Giovino AA, Hoebel BG.

Brain Res. 1984 Jan 16;291(1):119-24.

PMID:
6320951

Supplemental Content

Loading ...
Support Center